Terminal complement inhibition in atypical haemolytic uremic syndrome: a single-centre experience
In this Romanian aHUS cohort, CFI variants were more frequent than expected, probably reflecting a different geographical distribution. Anti-C5 therapy proved effective and safe. However, limited patient numbers and observational design are study limitations.
Authors
- Sonia Bălănică
- Elena Georgia Micu
- Adrian Lungu (ORCID: https://orcid.org/0000-0003-2025-3315)
- Cristina Căpușă (ORCID: https://orcid.org/0000-0002-3748-8164)
- Roxana Jurubiță (ORCID: https://orcid.org/0000-0002-1955-8579)
- Gener Ismail (ORCID: https://orcid.org/0000-0003-3306-189X)
- Valentin Mocanu (ORCID: https://orcid.org/0000-0001-7855-6242)
- Bogdan Sorohan (ORCID: https://orcid.org/0000-0003-3574-4635)
- Gabriel Mircescu (ORCID: https://orcid.org/0000-0002-8606-3699)
- Bogdan Obrișcă (ORCID: https://orcid.org/0000-0003-4796-4950)
- C. Achim
Institutions
- Carol Davila University of Medicine and Pharmacy (RO)
- Institutul Clinic Fundeni (RO)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-11-17
- DOI
- https://doi.org/10.3389/fphar.2025.1683188
- Primary Topic
- Complement system in diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Semmelweis Egyetem